In May ----, Egyptian health minister Ahmed Rady announced a -- price rise for all Egyptian medicines priced up to EGP-- (USD-.--) -including a large proportion of generic medicines. ...-including a large proportion of generic medicines. A new proposal for advancing public health in Egypt, with a focus on four main outcomes was put forward in ----: Human capital development, reforming the national health insurance scheme, reducing the hepatitis C burden, and improving public healthcare facilities. Egypt s evolving demographic and epidemiological profile will support pharmaceutical growth over the long-term. ...Plans to promote science in the country open opportunities for contract research organisations and clinical trial outsourcing. A much needed entrance by an active pharmaceutical ingredients manufacturer would cut the import bill significantly and allow the domestic drugmakers to thrive and, ultimately, boost economic growth in this sector.
...Strict pricing controls and reference pricing system reduces innovative drugmaker profits. Per-capita drug spending in Egypt is among the lowest in the Middle East. ...Patent laws remain notably below international standards, with data protection and enforcement being major concerns. The market is reliant on imports of high-tech products, as well as of raw materials, and thus vulnerable to currency fluctuations resulting in medicine shortages. High proportion of counterfeit drugs in the market. ...The market is reliant on imports of high-tech products, as well as of raw materials, and thus vulnerable to currency fluctuations resulting in medicine shortages. High proportion of counterfeit drugs in the market.
...Egypt presents a moderately attractive commercial opportunity for multinational pharmaceutical companies. Egypt s medium-term growth is positive and has improved significantly over the past year in line with an improving political situation, albeit with persisting instabilities. ...